Statements (54)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:superhero
|
gptkbp:activities |
adrenergic agonist
|
gptkbp:approves |
gptkb:FDA
|
gptkbp:brand |
gptkb:Asthmanefrin
|
gptkbp:clinical_trial |
Phase 3
NC T01234567 as needed for asthma symptoms |
gptkbp:contraindication |
severe asthma attacks
|
gptkbp:current_use |
chronic obstructive pulmonary disease
|
gptkbp:dosage_form |
metered-dose inhaler
|
gptkbp:education |
how to use inhaler
recognizing asthma symptoms when to seek emergency care |
gptkbp:feedback |
generally well tolerated
effective for quick relief |
gptkbp:formulation |
aerosol
liquid solution |
https://www.w3.org/2000/01/rdf-schema#label |
Asthmanefrin
|
gptkbp:indication |
relief of bronchospasm
|
gptkbp:ingredients |
racepinephrine
|
gptkbp:interacts_with |
MAO inhibitors
beta-blockers tricyclic antidepressants |
gptkbp:is_available_on |
prescription medication
|
gptkbp:is_used_for |
asthma treatment
|
gptkbp:manager |
inhalation
|
gptkbp:manufacturer |
Medi Natura
|
gptkbp:marketed_as |
gptkb:Australia
gptkb:United_Kingdom gptkb:United_States gptkb:Native_American_tribe |
gptkbp:packaging |
aerosol canister
|
gptkbp:pharmacokinetics |
rapid onset of action
|
gptkbp:population |
adults and children over 4 years
|
gptkbp:provides_information_on |
National Asthma Education and Prevention Program
|
gptkbp:regulatory_compliance |
FDA approval in 2013
|
gptkbp:research |
asthma management strategies
|
gptkbp:safety_features |
post-marketing surveillance
not for use in patients with heart disease |
gptkbp:scholarships |
consult healthcare provider before use
|
gptkbp:shelf_life |
24 months
|
gptkbp:side_effect |
dizziness
headache nausea nervousness tremors increased heart rate |
gptkbp:storage |
room temperature
|
gptkbp:supply_chain |
available at pharmacies
|
gptkbp:treatment |
enhanced quality of life
improved lung function reduced asthma attacks |
gptkbp:bfsParent |
gptkb:formoterol
|
gptkbp:bfsLayer |
5
|